Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

We think its portfolio and pipeline support a wide moat, and with the HCV market stabilizing, Gilead needs strong continued innovation in HIV, solid oncology pipeline data, and smart future ...

Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced key executive appointments designed to accelerate the ...

Cindy Perettie; Executive Vice President of Kite; Gilead Sciences Inc. Geoffrey Meacham; Analyst; Citi. Terence Flynn; Analyst; Morgan Stanley. Timothy Anderson; Analyst; BofA Glo ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.

S&P 500 E-Mini futures (ESH25) are down -0.33%, andMarch Nasdaq 100 E-Mini futures (NQH25) are down -0.44% this morning as ...

Marking World Cancer Day 2025, this week's Executive Q&A is with Diego Santoro, General Manager & Head of International ...

Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the ...